文献速递前列腺癌

磁共振成像-超声融合与磁共振成像引导下靶向前列腺活检的比较有效性

Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-bore Magnetic Resonance Imaging-targeted Prostate Biopsy.
PubMed 文献 · Urology · 2022-10-04

本研究比较了磁共振成像-超声融合活检与磁共振成像引导下靶向活检的前列腺癌检出率。共纳入280例患者(346个病灶),23.9%为Gleason 6前列腺癌主动监测者。按患者分析两种方法总体检出率和临床显著检出率无显著差异;按病灶分析磁共振引导靶向活检的临床显著检出率更高(32.8% vs 21.4%,P=0.02)。

要点

  • 按患者分析,MRI-超声融合与MRI引导靶向活检的总体和临床显著癌检出率无显著差异。
  • 按病灶分析,MRI引导靶向活检的临床显著癌检出率高于MRI-超声融合活检(32.8% vs 21.4%,P=0.02)。
  • 作者建议行MRI-超声融合活检时应同时获取系统穿刺针。

核心结论

  • 按患者分析,MRI-超声融合活检与MRI引导靶向活检的癌检出率无统计学显著差异。
  • 仅考虑靶向穿刺针时,MRI引导靶向活检与更高的临床显著癌检出率相关。
  • 作者建议行MRI-超声融合活检时应获取系统穿刺针。

研究设计与样本

  • 研究纳入18-89岁因PSA升高或Gleason 6前列腺癌主动监测而行前列腺活检的男性。
  • MRI-超声融合活检为12针系统穿刺加靶向穿刺,在诊室进行;MRI引导靶向活检仅行靶向穿刺。
  • 共纳入280例患者(346个病灶),其中23.9%为Gleason 6前列腺癌主动监测者。
  • 比较不同活检技术的癌检出率(Gleason 6-10)和临床显著癌检出率(Gleason 7-10),并校正患者和影像学特征。

主要发现

  • 按患者分析,MRI-超声融合活检与MRI引导靶向活检的校正总体癌检出率分别为64.1%与54.2%(P=0.24),无统计学显著差异。
  • 按患者分析,MRI-超声融合活检与MRI引导靶向活检的校正临床显著癌检出率分别为36.5%与37.9%(P=0.85),无统计学显著差异。
  • 按病灶分析,MRI-超声融合活检与MRI引导靶向活检的校正总体癌检出率分别为45.7%与50.1%(P=0.49),无统计学显著差异。
  • 按病灶分析,MRI引导靶向活检的临床显著癌检出率高于MRI-超声融合活检(32.8% vs 21.4%,P=0.02)。

临床怎么用

  • 作者建议,行MRI-超声融合活检时应获取系统穿刺针。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine the comparative effectiveness of magnetic resonance imaging-ultrasound (MRI-U/S) fusion biopsy and in-bore MRI-targeted biopsy. METHODS: We identified men aged 18-89 with a diagnosis of elevated prostate specific antigen (PSA) or Gleason 6 prostate cancer on active surveillance who underwent MRI-U/S fusion prostate biopsy (12-core + targeted) in the office or in-bore MRI-targeted biopsy (MRI-IB; targeted only). The cancer detection rate (CDR; Gleason 6-10) and clinically significant CDR (csCDR; Gleason 7-10) were compared across biopsy techniques, adjusted for patient and radiographic features. RESULTS: A total of 280 patients (346 lesions) were included, of whom 23.9% were on active surveillance for Gleason 6 prostate cancer. In the per-patient analyses, there was no statistically significant difference in adjusted overall CDR (64.1% vs 54.2%; P = .24) or csCDR (36.5% vs 37.9%; P = .85) between MRI-U/S and MRI-IB biopsy. In the per-lesion analyses, there was no statistically significant difference in adjusted overall CDR (45.7% vs 50.1%; P = .49) between MRI-U/S and MRI-IB biopsy, but MRI-IB biopsy was associated with a higher csCDR than MRI-U/S biopsy (32.8% vs 21.4%; P = .02). CONCLUSION: We observed no statistically significant differences in cancer detection rates between MRI-U/S fusion biopsy and MRI-IB biopsy in per-patient analyses. However, MRI-IB biopsy was associated with higher csCDR when considering targeted biopsy cores only. These results suggest that systematic cores should be obtained when performing MRI-U/S fusion biopsy.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Ramos F, Korets R, Fleishman A, et al. Comparative Effectiveness of Magnetic Resonance Imaging-Ultrasound Fusion Versus In-bore Magnetic Resonance Imaging-targeted Prostate Biopsy. Urology. 2022. PMID: 36206828. doi:10.1016/j.urology.2022.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。